Form 4: IQVIA GC Eric Sherbet Granted 12,112 Stock Appreciation Rights

IQVIA Holdings Inc.'s Executive Vice President and General Counsel, Eric Sherbet, was granted 12,112 Stock Appreciation Rights on February 9, 2026.

Summary

• Eric Sherbet, Executive Vice President and General Counsel of IQVIA Holdings Inc., was granted 12,112 Stock Appreciation Rights (SARs).
• The SARs have an exercise price of $192.67.
• The grant date for these SARs was February 9, 2026.
• These SARs will vest in three annual installments, beginning on February 9, 2027.
• The expiration date for these SARs is February 9, 2036.
• Following this transaction, Eric Sherbet beneficially owns 12,112 derivative securities directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices designed to align management's long-term interests with shareholder value creation.

Positives

• The grant of Stock Appreciation Rights aligns management's interests with shareholder value creation.
• The vesting schedule encourages long-term commitment from a key executive.

Negatives

• No immediate cash inflow for the executive, as these are derivative securities that vest over time and depend on future stock price performance.

Risks

• The value of the Stock Appreciation Rights is dependent on the future stock price performance of IQVIA Holdings Inc.
• If the stock price does not increase above the exercise price of $192.67, the SARs may have limited or no value.

Future Outlook

The filing indicates a long-term incentive structure for a key executive, suggesting an expectation of future stock price appreciation over the next decade.

Industry Context

StockSavvy.ai notes that granting Stock Appreciation Rights is a common executive compensation practice in the healthcare technology and life sciences industries, aiming to align executive incentives with long-term shareholder value creation, similar to practices seen at companies like Veeva Systems or Cerner (now Oracle Health).

Comparison to Industry Standards

• The grant of SARs with a 10-year expiration and multi-year vesting is consistent with typical long-term incentive plans for senior executives in large-cap technology and healthcare companies.
• Companies such as Thermo Fisher Scientific and Danaher often utilize similar equity-based compensation structures to retain talent and incentivize performance.
• The specific exercise price of $192.67 would be compared against IQVIA's stock price on the grant date to assess if it was at-the-money, which is standard for SAR grants.

Related Party Transactions

• Grant of 12,112 Stock Appreciation Rights to Executive Vice President, General Counsel Eric Sherbet as part of his compensation package.

Stakeholder Impact

• Shareholders: Potential positive impact if the SARs incentivize the executive to drive stock price appreciation, aligning interests.
• Employees: No direct impact on general employees, but reflects the company's executive compensation strategy.

Next Steps

• The Stock Appreciation Rights will begin to vest in three annual installments starting February 9, 2027.
• The executive may exercise the vested SARs at any point before the expiration date of February 9, 2036, assuming the stock price is above the exercise price.

Key Dates

Recommendation

This Form 4 reports a standard executive compensation grant of Stock Appreciation Rights, which is a routine event and does not provide new fundamental information to alter an investment thesis. It aligns executive incentives with long-term shareholder value but does not signal an immediate catalyst for a 'buy' or 'sell' recommendation.

Keywords

IQVIA Holdings Inc., IQV, Stock Appreciation Rights, SARs, Insider Transaction, Executive Compensation, Form 4, Eric Sherbet, General Counsel